ClinConnect ClinConnect Logo
Search / Trial NCT05375383

Microbial Colonization of Oral Probiotics

Launched by BLIS TECHNOLOGIES LIMITED · May 11, 2022

Trial Information

Current as of August 11, 2025

Unknown status

Keywords

Streptococcus Salivarius K12 Probiotic Microbial Colonization Oral Probiotic Lozenges Powder Prebiotic Streptococcus Salivarius M18

ClinConnect Summary

This is a double-blind, randomized controlled colonization pilot study with no cross over to evaluate the colonization efficacy of lozenges and powders containing two different commercially available probiotic bacteria (S. salivarius K12 ) or S. salivarius M18 with or without 2 different prebiotic sugars or their combinations.

Participants will be randomly assigned to one of the 12 groups consuming probiotic lozenge or powder containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotics (e.g. sugars that may promote probiotic activity) over a seven day period. Sal...

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 1. Male or Female 18y - 80y age
  • 2. In general good health 18 - 80 years of age.
  • 3. Practice good oral hygiene.
  • Exclusion criteria:
  • 1. Have a history of autoimmune disease or are immunocompromised.
  • 2. Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
  • 3. History of allergy (e.g. dairy).

About Blis Technologies Limited

Blis Technologies Limited is an innovative biotechnology company focused on the development and commercialization of advanced microbial therapies for a range of health applications. With a commitment to harnessing the power of beneficial bacteria, the company specializes in research and clinical trials aimed at enhancing oral and systemic health through its proprietary probiotic formulations. Leveraging cutting-edge technology and a strong scientific foundation, Blis Technologies Limited strives to improve patient outcomes and contribute to the growing field of microbiome research, positioning itself as a leader in the development of safe and effective therapeutic solutions.

Locations

Dunedin, Otago, New Zealand

Patients applied

0 patients applied

Trial Officials

John D Hale, PhD

Study Director

Blis Technologies Ltd

Rohit Jain, PhD

Principal Investigator

Blis Technologies Ltd, Dunedin, New Zealand

John R Tagg, PhD

Principal Investigator

Blis Technologies Ltd, Dunedin, New Zealand

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials